Navigation Links
Half-Dose Flu Shot Works Well in Young Adults
Date:12/8/2008

the validity of a dose reduction strategy in the setting of vaccine shortages," the researchers wrote. "Reduced dosing could have a significant impact on the response to vaccine shortages, particularly at a local level when faced with considerable delays in vaccine supply delivery."

Engler and colleagues also found that women of all ages had a greater immune response to both doses of the flu vaccine than men. Women who received the half dose had similar antibody responses as men who received the full dose.

"These findings suggest that guidelines for vaccine use during shortages should take sex, as well as age, into consideration. As recommendations for influenza expand and evidence that elderly persons [men older than 60 years] may require higher doses of vaccine for optimal responses, reduced doses in healthy, younger populations may become a valuable national strategy," the study authors concluded.

Instead of trying to find ways to stretch vaccine supplies, better methods of flu vaccine production are needed, Dr. Ann R. Falsey, of Rochester General Hospital, N.Y., said in an accompanying editorial.

"Although the results of this study are useful and can provide a guide to extending the vaccine supply during periods of shortage, perhaps the real message of this study is that better methods of influenza vaccine production that are less prone to problems are clearly needed," she wrote.

More information

The U.S. Centers for Disease Control and Prevention has more about preventing seasonal flu.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, Dec. 8, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Start 2009 with The Chopra Centers Signature Self-Empowerment Workshop
2. PAHEF Works to Prevent Violence Against Women
3. Major Retailers Experience 161% Increase in Attempted Hacker Attacks, According to SecureWorks
4. Over-the-Phone Weight Loss Counseling Works
5. International workshop aims to boost public engagement work in developing countries
6. BET Networks Joins the International Call to Stop the Spread of HIV on World AIDS Day Monday, December 1 with a Special Episode of 106 & PARK Followed by BET News Exclusive ARE YOU POSITIVE?
7. HHS AIDS.gov to Use Blogs, Virtual Worlds, and Social Networks to Deliver HIV Information for World AIDS Day 2008
8. Agito Networks Names New CEO, Broadens Depth of Experience of Enterprise Mobility Leader
9. Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations
10. Employers Want National Approach to Health Care—Still Believe Employer-Based System Works Best: New Survey Looks At Attitudes toward Health Care Reform and Major Health Care Issues.
11. Nurture(R) by Steelcase Wins Second Consecutive Nightingale Award for SYNC(TM) Caregiver Workspace Solution
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Half-Dose Flu Shot Works Well in Young Adults
Half-Dose Flu Shot Works Well in Young Adults
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 1Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 1Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 2Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 4Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 5Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 1Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 2